Literature DB >> 11549352

Tissue distribution and functional expression of a cDNA encoding a novel mixed lineage kinase.

L J Bloem1, T R Pickard, S Acton, M Donoghue, R C Beavis, M D Knierman, X Wang.   

Abstract

Hypertrophy is an adaptive response of the heart to myocardial injury or hemodynamic overload that may progress and contribute to cardiac decompensation and eventually to heart failure. The signaling pathways controlling this response in the cardiac myocyte are poorly understood. A data mining effort of a human failed heart cDNA library was undertaken in an effort to identify novel signaling molecules involved in cardiac hypertrophy. This effort identified a novel kinase (MLK7) homologous to the mixed lineage kinase family of proteins. The mixed lineage kinases are mitogen-activated protein kinase kinase kinases (MAPKKKs) which activate stress activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) and p38 kinase pathways. They contain a catalytic domain with homology to both serine/threonine and tyrosine-specific kinases and a dual leucine zipper. MLK7 is identical to leucine zipper and sterile-alpha motif protein kinase (ZAK) through the leucine zipper domain but has a completely divergent COOH-terminus and shares approximately 40% homology with the other MLKs overall. Expression of MLK7 mRNA is most abundant in skeletal muscle and heart, with expression restricted to the cardiac myocyte. The recombinant histidine tagged MLK7 expressed and purified from insect cells exhibited serine/threonine kinase activity in vitro with myelin basic protein as substrate. When expressed in cardiac myocytes, MLK7 activated SAPK/JNK1, and ERK and p38 to a lesser extent. Additionally, MLK7 altered fetal gene expression and increased protein synthesis in cardiac myocytes. These data suggest that MLK7 is a new member of the mixed lineage kinase family that modulates cardiac SAPK/JNK pathway and may play a role in cardiac hypertrophy and progression to heart failure. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549352     DOI: 10.1006/jmcc.2001.1437

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  11 in total

1.  Activation of the Classical Mitogen-Activated Protein Kinases Is Part of the Shiga Toxin-Induced Ribotoxic Stress Response and May Contribute to Shiga Toxin-Induced Inflammation.

Authors:  Dakshina M Jandhyala; Amrita Ahluwalia; Jennifer J Schimmel; Arlin B Rogers; John M Leong; Cheleste M Thorpe
Journal:  Infect Immun       Date:  2015-10-19       Impact factor: 3.441

2.  ZAKβ Alleviates Oxidized Low-density Lipoprotein (ox-LDL)-Induced Apoptosis and B-type Natriuretic Peptide (BNP) Upregulation in Cardiomyoblast.

Authors:  Ying-Ming Liou; Chih-Yang Huang; Yueh-Min Lin; Jiro Hasegawa Situmorang; Jia-Zun Guan; Dennis Jine-Yuan Hsieh; Jaw-Ji Yang; Michael Yu-Chih Chen; Ching-Hui Loh; Chia-Hua Kuo; Shang-Yeh Lu
Journal:  Cell Biochem Biophys       Date:  2022-07-01       Impact factor: 2.989

3.  Structure of the Human Protein Kinase ZAK in Complex with Vemurafenib.

Authors:  Sebastian Mathea; Kamal R Abdul Azeez; Eidarus Salah; Cynthia Tallant; Finn Wolfreys; Rebecca Konietzny; Roman Fischer; Hua Jane Lou; Paul E Brennan; Gisela Schnapp; Alexander Pautsch; Benedikt M Kessler; Benjamin E Turk; Stefan Knapp
Journal:  ACS Chem Biol       Date:  2016-03-31       Impact factor: 5.100

4.  The mixed-lineage kinase 1-3 signalling pathway regulates stress response in cardiac myocytes via GATA-4 and AP-1 transcription factors.

Authors:  A Ola; R Kerkelä; H Tokola; S Pikkarainen; R Skoumal; O Vuolteenaho; H Ruskoaho
Journal:  Br J Pharmacol       Date:  2010-01-08       Impact factor: 8.739

5.  The MAP3K ZAK, a novel modulator of ERK-dependent migration, is upregulated in colorectal cancer.

Authors:  C Rey; B Faustin; I Mahouche; R Ruggieri; C Brulard; F Ichas; I Soubeyran; L Lartigue; F De Giorgi
Journal:  Oncogene       Date:  2015-11-02       Impact factor: 9.867

6.  Recessive mutations in the kinase ZAK cause a congenital myopathy with fibre type disproportion.

Authors:  Nasim Vasli; Elizabeth Harris; Jason Karamchandani; Eric Bareke; Jacek Majewski; Norma B Romero; Tanya Stojkovic; Rita Barresi; Hichem Tasfaout; Richard Charlton; Edoardo Malfatti; Johann Bohm; Chiara Marini-Bettolo; Karine Choquet; Marie-Josée Dicaire; Yi-Hong Shao; Ana Topf; Erin O'Ferrall; Bruno Eymard; Volker Straub; Gonzalo Blanco; Hanns Lochmüller; Bernard Brais; Jocelyn Laporte; Martine Tétreault
Journal:  Brain       Date:  2016-11-05       Impact factor: 13.501

7.  BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling.

Authors:  Harina Vin; Sandra S Ojeda; Grace Ching; Marco L Leung; Vida Chitsazzadeh; David W Dwyer; Charles H Adelmann; Monica Restrepo; Kristen N Richards; Larissa R Stewart; Lili Du; Scarlett B Ferguson; Deepavali Chakravarti; Karin Ehrenreiter; Manuela Baccarini; Rosamaria Ruggieri; Jonathan L Curry; Kevin B Kim; Ana M Ciurea; Madeleine Duvic; Victor G Prieto; Stephen E Ullrich; Kevin N Dalby; Elsa R Flores; Kenneth Y Tsai
Journal:  Elife       Date:  2013-11-05       Impact factor: 8.140

8.  A Novel Zak Knockout Mouse with a Defective Ribotoxic Stress Response.

Authors:  Dakshina M Jandhyala; John Wong; Nicholas J Mantis; Bruce E Magun; John M Leong; Cheleste M Thorpe
Journal:  Toxins (Basel)       Date:  2016-09-02       Impact factor: 4.546

9.  Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin.

Authors:  John Wong; Logan B Smith; Eli A Magun; Thomas Engstrom; Kirsten Kelley-Howard; Dakshina M Jandhyala; Cheleste M Thorpe; Bruce E Magun; Lisa J Wood
Journal:  Cancer Biol Ther       Date:  2012-10-31       Impact factor: 4.742

10.  A chemoproteomic platform to quantitatively map targets of lipid-derived electrophiles.

Authors:  Chu Wang; Eranthie Weerapana; Megan M Blewett; Benjamin F Cravatt
Journal:  Nat Methods       Date:  2013-12-01       Impact factor: 28.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.